TY - JOUR
T1 - Nanoghosts
T2 - Mesenchymal Stem cells derived nanoparticles as a unique approach for cartilage regeneration
AU - D'Atri, D.
AU - Zerrillo, L.
AU - Garcia, J.
AU - Oieni, J.
AU - Lupu-Haber, Y.
AU - Schomann, T.
AU - Chan, A.
AU - Cruz, L. J.
AU - Creemers, L. B.
AU - Machluf, Marcelle
N1 - Funding Information:
This project has received funding from Technion Israel Insitute of Technology .
Funding Information:
This project has received funding from the European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement No 642414 .
Funding Information:
This project has received funding from the European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement No 642414.This project has received funding from Technion Israel Insitute of Technology.The funding by the Dutch Arthritis Association (LLP12) is gratefully acknowledged.
Publisher Copyright:
© 2021
PY - 2021/9/10
Y1 - 2021/9/10
N2 - Osteoarthritis (OA) is a chronic degenerative disease, which affects the joints and is characterized by inflammation, cartilage loss and bone changes. Nowadays, there are no treatments for OA, and current therapies are focused on relieving the symptoms. As a new therapy approach, micro and nanoparticles have been extensively explored and among all the studied particles, the use of cell-membrane-based particles is expanding. Another promising approach studied to treat OA, is the use of mesenchymal stem cells (MSCs) which play an important role modulating inflammation. We developed a novel kind of MSCs' cytoplasmic-membrane-based nanoparticles, termed nano-ghosts (NGs). Retaining MSCs' surface properties and lacking cells' internal machinery allow the NGs to have immunomodulatory capacity and to be immune-evasive while not susceptible to host-induced changes. In this study, we demonstrate NGs' ability to target cartilage tissues, in vitro and in vivo, while modulating the inflammatory process. In vivo studies demonstrated NGs ability to act as an immunomodulatory drug slowing down cartilage degeneration process. Our proof-of-concept experiments show that NGs system is a versatile nano-carrier system, capable of therapeutics loading, with targeting capabilities towards healthy and inflamed cartilage cells. Our results, along with previously published data, clearly reveal the NGs system as a promising nano-carrier platform and as a potential immunomodulatory drug for several inflammation-related diseases.
AB - Osteoarthritis (OA) is a chronic degenerative disease, which affects the joints and is characterized by inflammation, cartilage loss and bone changes. Nowadays, there are no treatments for OA, and current therapies are focused on relieving the symptoms. As a new therapy approach, micro and nanoparticles have been extensively explored and among all the studied particles, the use of cell-membrane-based particles is expanding. Another promising approach studied to treat OA, is the use of mesenchymal stem cells (MSCs) which play an important role modulating inflammation. We developed a novel kind of MSCs' cytoplasmic-membrane-based nanoparticles, termed nano-ghosts (NGs). Retaining MSCs' surface properties and lacking cells' internal machinery allow the NGs to have immunomodulatory capacity and to be immune-evasive while not susceptible to host-induced changes. In this study, we demonstrate NGs' ability to target cartilage tissues, in vitro and in vivo, while modulating the inflammatory process. In vivo studies demonstrated NGs ability to act as an immunomodulatory drug slowing down cartilage degeneration process. Our proof-of-concept experiments show that NGs system is a versatile nano-carrier system, capable of therapeutics loading, with targeting capabilities towards healthy and inflamed cartilage cells. Our results, along with previously published data, clearly reveal the NGs system as a promising nano-carrier platform and as a potential immunomodulatory drug for several inflammation-related diseases.
UR - http://www.scopus.com/inward/record.url?scp=85111989851&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2021.05.015
DO - 10.1016/j.jconrel.2021.05.015
M3 - Article
C2 - 34015401
SN - 0168-3659
VL - 337
SP - 472
EP - 481
JO - Journal of controlled release : official journal of the Controlled Release Society
JF - Journal of controlled release : official journal of the Controlled Release Society
ER -